Verastem, Inc. Fair Value Adjustment of Warrants
Verastem, Inc. (VSTM) reported Fair Value Adjustment of Warrants of -$9.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- Verastem, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $0.00.
- Verastem, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$9.32M, a 485.89% decline year-over-year.
- Verastem, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$10.48M, a 132.16% decline year-over-year.
- Verastem, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $55.88M.
- Verastem, Inc. fair value adjustment of warrants for fiscal 2025 was $27.49M, a 43.57% increase from fiscal 2024.
- Verastem, Inc. fair value adjustment of warrants for fiscal 2024 was $19.15M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.32M 10-Q · filed 2026-08-06 | -$19.81M derived: sum of 3 quarters · filed 2026-08-06 | $36.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$9.32M 10-Q · filed 2026-05-07 | -$19.81M derived: sum of 2 quarters · filed 2026-05-07 | $36.07M derived: sum of 3 quarters · filed 2026-05-07 | $15.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $45.40M derived: sum of 2 quarters · filed 2026-03-04 | $25.08M derived: sum of 3 quarters · filed 2026-08-06 | $27.49M 10-K · filed 2026-03-04 |
| 2025-09-30 | $55.88M 10-Q · filed 2025-11-04 | $35.56M derived: sum of 2 quarters · filed 2026-08-06 | $37.98M 10-Q · filed 2025-11-04 | $70.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$20.32M 10-Q · filed 2026-08-06 | -$17.90M 10-Q · filed 2026-08-06 | $14.70M derived: sum of 3 quarters · filed 2026-08-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-07 | $35.02M derived: sum of 2 quarters · filed 2026-05-07 | $21.57M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $19.15M derived: sum of 2 quarters · filed 2026-03-04 | $19.15M 10-K · filed 2026-03-04 | |
| 2024-09-30 | -$13.46M 10-Q · filed 2025-11-04 | -$13.46M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |